Eric Bjerkholt - 11 Sep 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
11 Sep 2025
Net transactions value
-$728,024
Form type
4
Filing time
12 Sep 2025, 20:00:05 UTC
Previous filing
12 Aug 2025
Next filing
23 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BJERKHOLT ERIC CHIEF FINANCIAL OFFICER C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY /s/ Judit Ryvkin, Attorney-in-Fact 12 Sep 2024 0001197350

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise +18,333 +59% 49,523 11 Sep 2025 Direct F1
transaction MIRM Common Stock Sale $728,024 -9,578 -19% $76.01 39,945 12 Sep 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Restricted Stock Units Options Exercise $0 -18,333 -50% $0.000000 18,333 11 Sep 2025 Common Stock 18,333 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).
F2 Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F3 The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023.